BÖLÜM

33

Medüller Tiroid Kanseri

- Prof. Dr. Mehtap ÇAKIR
- Prof. Dr. Murat Faik ERDOĞAN

Özet

Parafolliküler C hücrelerinden gelişen medüller tiroid kanseri (MTK), son yıllarda artan papiller tiroid kanseri sıklığı nedeniyle artık tiroid kanserlerinin %1-2'sini oluşturmakla birlikte tiroid kanser morbidite ve mortalitesinde önemli yer tutmaktadır. MTK'ların yaklaşık %75'i sporadik iken, %25'i herediter olarak görülür. Sporadik MTK genellikle dördüncü ve altıncı dekadlarda, herediter MTK ise, aktive edici bir "germline" *RET* proto-onkogen mutasyonu sonucu otozomal dominant kalıtım şekli izleyerek multiple endokrin neoplazi tip 2 (MEN 2) sendromlarının ilk ve en sık görülen bileşeni olarak ilk dekadda bile ortaya çıkabilir. Bu yazıda MTK moleküler biyolojisi, patolojisi ve sekretuvar ürünleri, sporadik ve MEN2 ilişkili formları, cerrahi tedavisi, nüks ve metastatik formlarına yaklaşım, MEN2 sendromlarında MTK'ya yaklaşım ve ileri evre MTK'da sistemik tedavi özetlenmiştir.

Kaynaklar

1. Hazard JB, Hawk WA, Crile G Jr: Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959;19 (1):152-161.
2. Wells Jr SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid 2015;25(6):567-610.
3. Johansson E, Andersson L, Örnros J, et al. Revising the embryonic origin of thyroid C cells in mice and humans. Development 2015;142(20):3519-3528.
4. Filetti S, Durante C, Hartl D, et al; ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Sep 24. pii:mdz400. doi: 10.1093/annonc/mdz400.
5. Castinetti F, Moley J, Mulligan L, et al. A comprehensive review on MEN2B. Endocr Relat Cancer 2018;25(2):T29-T39.
6. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42(2):581-588.
7. Castellone MD, Melillo RM. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). Endocr Relat Cancer 2018;25(2):T105-T119.
8. Cakir M, Grossman AB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009;90(4):323-348.
9. Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer 2019;26(9):R499-R518.
10. Catalogue of Somatic Mutations in Cancer. Available online: https://cancer.sanger.ac.uk (accessed on 13 June 2019).
11. Vuong HG, Odate T, Ngo HT, et al. Clinical significance of RET and RAS mutations in sporadic medullary thyroid cancer-a meta-analysis. Endocr Relat Cancer 2018;25(6):633-641.
12. Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clinical Endocrinology 2010;72(4):534–542.
13. Fussey JM, Vaidya B, Kim D, et al. The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review. Clin Endocrinol (Oxf) 2019 Jul 13. doi: 10.1111/cen.14060.[Epub ahead of print]
14. Ciampi R, Mian C, Fugazzola L, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013;23(1):50-57.
15. Moura MM, Cavaco BM, Leite V. RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer 2015;22(5):R235-R252.
16. Aydoğan Bİ, Yüksel B, Tuna MM, ve ark. Distribution of RET mutations and evaluation of treatment approaches in hereditary medullary thyroid carcinoma in Turkey. J Clin Res Pediatr Endocrinol 2016;8(1):13-20.
17. Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008;18(8):895–899.
18. Trimboli P, Treglia G, Guidobaldi L, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf) 2015;82(2):280–285.
19. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6):2655–2663.
20. Erdogan MF, Gürsoy A, Ozgen G, ve ark. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 2005;28(9):806-809.
21. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007;31(10):1960-1965.
22. Amin MB, Edge SB, Greene FL, et al. (Eds.) AJCC Cancer Staging Manual, 8th Edition, New York: Springer; 2017.
23. Machens A, Hinze R, Thomusch O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26(1):22-28.
24. Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw 2010;8(5):549–556.
25. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 2012;97(4):1250–1257.
26. Park JH, Lee YS, Kim BW, et al. Skip lateral neck node metastases in papillary thyroid carcinoma. World J Surg 2012;36(4):743–747.
27. Machens A, Lorenz K, Dralle H. Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations. J Clin Endocrinol Metab 2014;99(2):E286-292.
28. Machens A, Dralle H. Surgical treatment of medullary thyroid cancer. Recent Results Cancer Res 2015;204:187-205.
29. Kiernan CM, Grubbs EG. Surgical management of Multiple Endocrine Neoplasia 1 and Multiple Endocrine Neoplasia 2. Surg Clin North Am 2019;99(4):693-709.
30. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28(5):767-772.
31. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6):2664-2671.
32. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-141.
33. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29):3639-3646.